An observational study in Heart Failure, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Status unknown at 2 sites in United Kingdom. Per ClinicalTrials.gov, last updated 2012-05-09.
Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational
Several large trials have shown that beta-blocker treatment reduces the risk of death and hospital admission in patients with symptomatic heart failure. Unfortunately, survey data suggests relatively poor utilisation of beta-blockers, despite ample evidence for good tolerability. Additionally there are several important unanswered questions, such as clinical efficacy for specific sub-populations (women, the elderly and patients with diabetes or other co-morbidities) and the effect of beta-blockers in combination with other medications. Previous meta-analyses, based on published tabular data, have been conducted although this approach has important biases and limitations.
We plan to perform a carefully conducted systematic review of individual patient data from the major randomised trials of beta-blockers in heart failure. The goals of this collaborative project are to clarify the overall efficacy of beta-blockers and identify sub-groups that show particular benefit, thereby increasing the use of beta-blockers, reducing adverse clinical outcomes and the high costs associated with this condition.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 18,240 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Royal Brompton & Harefield NHS Foundation Trust is the lead sponsor of 137 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Meta-Analysis of randomised controlled trials investigating mortality \& morbidity of placebo versus beta-blockers in heart failure
Exclusion Criteria:
Drug: Beta blocker
Other: Placebo
as determined by individual study
Also known as: Metoprolol, Bucindolol, Carvedilol, Bisoprolol, Nebivolol
in addition to usual care
Beta-blocker therapy improves overall mortality and morbidity in symptomatic heart failure in an individual patient meta-analysis
Time frame: variable (time to event)
Beta-blocker therapy improves mortality and morbidity in both elderly patients and women
Time frame: variable (time to event)
Beta-blocker therapy improves mortality and morbidity in patients with co-morbidities (diabetes, renal dysfunction, COPD, peripheral arterial disease or atrial fibrillation)
Time frame: variable (time to event)
The benefit of beta-blockers is not modified by concomitant cardiovascular therapy
Time frame: variable (time to event)
The benefit of beta-blockers is independent of left ventricular ejection fraction at baseline
Time frame: variable (time to event)
The clinical benefit is dependent on the resting heart rate achieved whatever the dose achieved or agent used
Time frame: variable (time to event)
Adverse side effects of beta blocker therapy do not significantly impact on clinical benefit (as a whole and in relevant sub-groups)
Time frame: variable (time to event)
This study is status unknown, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Brompton & Harefield NHS Foundation Trust